Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

Acute Myeloid Leukemia: What’s New on the Horizon

Access Activity

Overview / Abstract:

Rapid progress in the treatment of Acute Myeloid Leukemia (AML) has resulted in a substantial volume of new clinical literature and updated guidelines. 8 new therapies have been approved since 2017 alone. Clinicians must remain well-versed with novel treatment options for newly diagnosed patients and those with relapsed/refractory AML and need education on advances in targeted therapies for AML.

This expert live recording from a series of national visiting lecture series updates clinicians on the latest data from clinical trials and provides direction on integrating novel treatment strategies based on patient and disease characteristics into their practice. This activity also includes a downloadable resource to improve care for your AML patients featuring slides from the national visiting lecture series.

Expiration

Apr 22, 2021

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Webinar / Webcast / Video

Credits / Hours

1.00

Accreditation

ACCME

Is This Activity Certified for "Live" Credit?

YES

Presenters / Authors / Faculty

Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Keywords / Search Terms

ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Webcasts, Newsletter, Case Study, Live Meetings, Slidekit, Monograph, Journal, CPX-351, liposomal, cytarabine, daunorubicin, chemotherapy, t-AML, SEAMLESS study, Tyrosine kinase inhibitors, CALGB 10603 trial, relapsed AML, refractory AML, Naval Daver, MD, Gilteritinib, ADMIRAL trial, Enasidenib, venetoclax, Ivosidenib, azacytidine, IDH1 mutation, FLT3, NPM1, DNMT3a, IDH1, IDH2, TET2, RUNX1, p53, NRAS, CEBPa, WT1, Midostaurin, Gemtuzumab ozogamicin, Immunophenotyping, cytogenic testing, molecular testing Free CE CME Live CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map